Friday Nasdaq Biotechnology Ishares (IBB) $IBB opened at 232.81 hitting the high price of 233.07 and a day low of 227.70 with a total volume of 1,838,600. IBB had a previous close of 232.50 and has been seeing an average volume of 3,586,095.
Overall Average: 8% Sell
Recent stock forum discussions about IBB http://investorshangout.com/search?q=IBB&...mp;yt0=Go!
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off. (full story)
Pharma ETFs: A Safe Haven from the Biotech Stock Slump? - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Apr 28, 10:42AM CDT
Why investors may want to think about a play on the pharmaceutical ETFs if they want drug industry exposure. (full story)
iShares Nasdaq Biotechnology Index Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 2.46% Loss
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for... (full story)
Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:00AM CDT
Solid results from Gilead, but poor results from Amgen, look to have a big impact on these health care ETFs. (full story)
Pharma ETFs: A Better Healthcare Investment? - Video Blog
Eric Dutram - Zacks Investment Research - Wed Apr 23, 5:42PM CDT
How have pharma ETFs held up during the biotech selloff? (full story)
iShares Nasdaq Biotechnology Index Fund (IBB) : Buy @ $231.17
Trading Central - Tue Apr 22, 8:43AM CDT
From a technical view, the ETF is bouncing off a key rising trend line drawn from the bottom of October 2012. Regarding technical indicators, the weekly RSI is pushing above its 50 mark while the 20-week moving average is reversing up. On a... (full story)
'Fast Money' Recap: Following the Netflix Story
at The Street - Tue Apr 22, 4:00AM CDT
The trading panel discussed Netflix earnings and Valeant's hostile bid for Allergan. (full story)
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and... (full story)
iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 2.33%
Comtex SmarTrend(R) - Mon Apr 21, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $221.37 to a high of $227.34. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $226.39 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
The ongoing market correction has taken a serious toll on biotech stocks, especially among companies early in their development. The iShares Nasdaq Biotech Index , for instance, is down over 15% in the past month alone. Market corrections (and bull... (full story)
'Fast Money' Recap: Watch Where Bonds Are Headed
at The Street - Fri Apr 18, 4:00AM CDT
The trading panel discussed bonds, industrial stocks, Chipotle Mexican Grill and IBM. (full story)
Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index is up 80% over the last 2 years, it's... (full story)
IBB, CELG, BIIB, ALXN: ETF Inflow Alert
ETFChannel.com - Tue Apr 15, 10:15AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF where we have detected an approximate $290.9 million dollar inflow -- that's a 6.9%... (full story)
Are Biotechs Bad Medicine for the S&P 500?
George Budwell, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
The S&P 500 is a closely watched indicator of the U.S. economy that has started to falter over the past few weeks. Specifically, the S&P 500 is now down over 2% in the last month, although it's still up about 15% over the last year.... (full story)
3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Biotech stocks have been in near free-fall the past month, with the iShares Nasdaq Biotechnology Index dropping a noteworthy 15.4%. While this could be part of a general market correction, such a dramatic decline may indicate deeper issues with... (full story)
Overall Average: 8% Sell
Recent stock forum discussions about IBB http://investorshangout.com/search?q=IBB&...mp;yt0=Go!
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off. (full story)
Pharma ETFs: A Safe Haven from the Biotech Stock Slump? - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Apr 28, 10:42AM CDT
Why investors may want to think about a play on the pharmaceutical ETFs if they want drug industry exposure. (full story)
iShares Nasdaq Biotechnology Index Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 2.46% Loss
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for... (full story)
Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:00AM CDT
Solid results from Gilead, but poor results from Amgen, look to have a big impact on these health care ETFs. (full story)
Pharma ETFs: A Better Healthcare Investment? - Video Blog
Eric Dutram - Zacks Investment Research - Wed Apr 23, 5:42PM CDT
How have pharma ETFs held up during the biotech selloff? (full story)
iShares Nasdaq Biotechnology Index Fund (IBB) : Buy @ $231.17
Trading Central - Tue Apr 22, 8:43AM CDT
From a technical view, the ETF is bouncing off a key rising trend line drawn from the bottom of October 2012. Regarding technical indicators, the weekly RSI is pushing above its 50 mark while the 20-week moving average is reversing up. On a... (full story)
'Fast Money' Recap: Following the Netflix Story
at The Street - Tue Apr 22, 4:00AM CDT
The trading panel discussed Netflix earnings and Valeant's hostile bid for Allergan. (full story)
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and... (full story)
iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 2.33%
Comtex SmarTrend(R) - Mon Apr 21, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $221.37 to a high of $227.34. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $226.39 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
The ongoing market correction has taken a serious toll on biotech stocks, especially among companies early in their development. The iShares Nasdaq Biotech Index , for instance, is down over 15% in the past month alone. Market corrections (and bull... (full story)
'Fast Money' Recap: Watch Where Bonds Are Headed
at The Street - Fri Apr 18, 4:00AM CDT
The trading panel discussed bonds, industrial stocks, Chipotle Mexican Grill and IBM. (full story)
Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index is up 80% over the last 2 years, it's... (full story)
IBB, CELG, BIIB, ALXN: ETF Inflow Alert
ETFChannel.com - Tue Apr 15, 10:15AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF where we have detected an approximate $290.9 million dollar inflow -- that's a 6.9%... (full story)
Are Biotechs Bad Medicine for the S&P 500?
George Budwell, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
The S&P 500 is a closely watched indicator of the U.S. economy that has started to falter over the past few weeks. Specifically, the S&P 500 is now down over 2% in the last month, although it's still up about 15% over the last year.... (full story)
3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Biotech stocks have been in near free-fall the past month, with the iShares Nasdaq Biotechnology Index dropping a noteworthy 15.4%. While this could be part of a general market correction, such a dramatic decline may indicate deeper issues with... (full story)
